These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35145298)

  • 1. PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity.
    Sugiura D; Okazaki IM; Maeda TK; Maruhashi T; Shimizu K; Arakaki R; Takemoto T; Ishimaru N; Okazaki T
    Nat Immunol; 2022 Mar; 23(3):399-410. PubMed ID: 35145298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restriction of PD-1 function by
    Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
    Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.
    Zhang Y; Song Q; Cassady K; Lee M; Tang H; Zheng M; Wang B; Schones DE; Fu YX; Riggs AD; Martin PJ; Feng R; Zeng D
    Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2205085120. PubMed ID: 37036990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80.
    Kennedy A; Robinson MA; Hinze C; Waters E; Williams C; Halliday N; Dovedi S; Sansom DM
    EMBO J; 2023 Mar; 42(5):e111556. PubMed ID: 36727298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
    Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
    Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80.
    Kang-Pettinger T; Walker K; Brown R; Cowan R; Wright H; Baravalle R; Waters LC; Muskett FW; Bowler MW; Sawmynaden K; Coombs PJ; Carr MD; Hall G
    J Biol Chem; 2023 Jan; 299(1):102769. PubMed ID: 36470427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.
    Haile ST; Horn LA; Ostrand-Rosenberg S
    Cancer Immunol Res; 2014 Jul; 2(7):610-5. PubMed ID: 24819296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Binds to B7-1 Only
    Chaudhri A; Xiao Y; Klee AN; Wang X; Zhu B; Freeman GJ
    Cancer Immunol Res; 2018 Aug; 6(8):921-929. PubMed ID: 29871885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration.
    Piao W; Li L; Saxena V; Iyyathurai J; Lakhan R; Zhang Y; Lape IT; Paluskievicz C; Hippen KL; Lee Y; Silverman E; Shirkey MW; Riella LV; Blazar BR; Bromberg JS
    Nat Commun; 2022 Apr; 13(1):2176. PubMed ID: 35449134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Context-restricted PD-(L)1 checkpoint agonism by CTLA4-Ig therapies inhibits T cell activity.
    Oxley EP; Kershaw NJ; Louis C; Goodall KJ; Garwood MM; Jee Ho SM; Voo VTF; Park HY; Iaria J; Wong LLL; Lebenbaum AG; Wiranata S; Pang ES; Edwards ESJ; D'Silva DB; Hansen J; van Zelm MC; O'Keeffe M; Hogarth PM; Haynes NM; Huntington ND; Wicks IP; Dickins RA
    Cell Rep; 2024 Oct; 43(10):114834. PubMed ID: 39383033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD80 Expressed by CD8
    Rollins MR; Gibbons Johnson RM
    J Immunol Res; 2017; 2017():7659462. PubMed ID: 29181416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific manner.
    Schuster C; Brosi H; Stifter K; Boehm BO; Schirmbeck R
    PLoS One; 2013; 8(8):e71746. PubMed ID: 23977133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
    J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation anxiety: Splitting PD-L1 from CD80 suppresses autoimmunity.
    Bracey NA; Maltzman JS
    Sci Immunol; 2022 Apr; 7(70):eabq1728. PubMed ID: 35363545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/CD80
    Zhang LZ; Yang JG; Chen GL; Xie QH; Fu QY; Xia HF; Li YC; Huang J; Li Y; Wu M; Liu HM; Wang FB; Yi KZ; Jiang HG; Zhou FX; Wang W; Yu ZL; Zhang W; Zhong YH; Bian Z; Yang HY; Liu B; Chen G
    Nat Commun; 2024 May; 15(1):3884. PubMed ID: 38719909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
    Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
    J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.